US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly & Co. won the backing of European Union regulators for its Alzheimer’s... Meta Platforms Inc. will stop selling political and issue-focused advertising in... Albert Manifold isn’t the first ...

We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts ...

Shares of Eli Lilly & Co. LLY rallied 2.89% to $798.89 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to 6,358.91 ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.